We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global Molecular Diagnostics Market to Reach USD 13.87 Billion by 2025

By LabMedica International staff writers
Posted on 06 Jul 2019
The global molecular diagnostics market was valued at USD 8 billion in 2017 and is projected to grow at a CAGR of 7.1% during the period 2018 to 2025 to reach USD 13.87 billion by 2025. More...
The presence of a robust supply chain network and favorable R&D strategies are enabling the players to establish a strong foothold in the global molecular diagnostics market. Additionally, increasing investments in cost management will create growth opportunities in the molecular diagnostics market.

These are the latest findings of Fortune Business Insights (Pune, Maharashtra, India), a market research firm.

Currently, the increasing incidence of microbial outbreaks is boosting the market for molecular diagnostics. For instance, major outbreaks of bacterial and viral infections in the Middle East and Africa have compelled all government and research institutions worldwide to adopt molecular diagnostics for inhibiting microbial outbreaks. The demand for molecular diagnosis is expected to rise due to the increasing prevalence of infectious diseases in both the developing and developed nations.

Awareness programs aimed at spreading awareness on infectious diseases and relevant preventive measures as adopted by the World Bank, World Health Organization (WHO), and other international organizations are also contributing to the growth of the molecular diagnostics market. The huge amount of resource engagement in terms of expertise, technology, and finance along with favorable environment for the simulation of research projects, especially for infectious diseases will fuel the market growth.

Based on technique, the amplification technique segment is expected to hold a major share of the molecular diagnostics market. On the basis of product type, the reagent and consumables segment is expected to grow at a significant rate during the forecast period. Based on application, the infectious disease segment was valued at USD 4.8 billion in 2017.

Geographically, North America is likely to dominate the global molecular diagnostics market due to the presence of major players in the region and collaborative efforts by large academic institutions and hospital research organizations to improve clinical efficiency. The molecular diagnostics market in Europe is also likely to witness a remarkable growth due to the rising adoption of molecular diagnostics by clinical microbiology organizations and bigger hospitals in the region. The Asia Pacific molecular diagnostics market is currently in the premature stage, although the rapidly developing healthcare and medical infrastructure and increasing investments in R&D in the region are likely to create growth opportunities over the coming years.

Related Links:
Fortune Business Insights


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.